New England IP Blog

Covering intellectual property developments in New England, and other developments that impact New England companies.

Category Archives: Pharmaceuticals

Subscribe to Pharmaceuticals RSS Feed

Barbic to Host Webinar on Recent Patent Eligibility Decisions

Recent decisions in patent cases from the Supreme Court, Federal Circuit and the Patent Trial and Appeal Board (PTAB) continue to shape the patent litigation landscape. Additionally, the United States Patent and Trademark Office (USPTO) occasionally updates its patent eligibility guidance to illustrate how patent examiners should evaluate claims for patent subject matter eligibility under … Continue Reading

Final Judgment Prescribed For Antibody Patent After Double Patenting Decision

We previously wrote about Judge Wolf’s decision to invalidate Janssen Biotech, Inc.’s (“Janssen”) biopharmaceutical patent (U.S. Patent No. 6,284,471 (the “’471 Patent”)), based on the doctrine of obviousness-type double patenting. Celltrion Healthcare Co. Inc. (“Celltrion”) subsequently moved the court for an entry of final judgment dismissing Janssen’s infringement claims premised on the ’471 Patent.  While … Continue Reading

Biosimilars Update

Novartis came one step closer to becoming the first company to offer a biosimilar drug for sale in the United States. Last month, an independent panel voted 14-0 to recommend FDA approval of Sandoz’s (Novartis’ generics division) application for its proposed ZarxioTM cancer drug – a generic version of Amgen’s patented Neupogen®. The decision is … Continue Reading

SCOTUS Brings More Certainty to District Court Claim Constructions

Since at least 1996, the Federal Circuit has reviewed district court claim constructions de novo.  This de novo standard introduced great uncertainty into patent cases:  A favorable claim construction, even one supported by detailed factual findings by the district court, could be set aside by the Federal Circuit without any deference whatsoever.  This situation surely … Continue Reading

Hurry Up if You Want to Wait

In a recent decision on a motion to stay litigation pending a Covered Business Method review filed by defendant Carecloud Corporation, District Judge Indira Talwani gave defendants good reason not to delay any petitions for patent office review. Established by the America Invents Act, Covered Business Method reviews may be filed by parties who have been … Continue Reading

Motion to Amend Infringement Contentions Denied Based on Futility

District Judge Nathaniel Gorton denied a plaintiff’s motion for leave to amend its infringement contentions, finding the amendments, if allowed, would be “futile.” This eventful case involves Amphastar Pharmaceuticals’ alleged infringement of Momenta Pharmaceuticals’ patent covering procedures related to an anticoagulant drug marketed as Lovenox (generically known as enoxaparin). Momenta filed suit in September, 2011, days after … Continue Reading
LexBlog